HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Pulmonary tuberculosis — Clinical Guidelines

Overview

Pulmonary tuberculosis (TB) is a contagious infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs, leading to significant morbidity and mortality worldwide. 1 8

Diagnosis

Clinical Symptoms: Persistent cough, fever, night sweats, weight loss.

Microbiological Tests: Sputum smear microscopy and culture; Xpert MTB/RIF Ultra assay for rapid diagnosis and rifampicin resistance detection. 2 17 18

Imaging: Chest X-ray and CT scans showing characteristic lesions.

Nucleic Acid Amplification Tests (NAATs): LC-aNAATs on respiratory and stool samples, especially useful in pediatric populations. 3

Metagenomic Next-Generation Sequencing (mNGS): Emerging tool for diagnosis, though evidence is still accumulating. 5

Animal Detection: African giant pouched rats for rapid screening in resource-limited settings. 15

Management

First-Line Drugs: Isoniazid, rifampicin, ethambutol, pyrazinamide for initial intensive phase (2 months), followed by continuation phase (4-7 months) with isoniazid and rifampicin. 10 19

Adjunctive Therapy: Vitamin D supplementation, particularly in deficient patients, to potentially improve treatment outcomes. 7 21 26

Drug Resistance: Use Xpert MTB/XDR for detection of multidrug-resistant TB and resistance to additional drugs. 9

Monitoring: Regular sputum smear microscopy and culture to monitor treatment efficacy.

Special Populations

Pregnancy: Evaluate maternal and perinatal outcomes carefully; standard anti-TB therapy is generally considered safe but requires close monitoring. 12

Pediatrics: Utilize LC-aNAATs and lateral flow lipoarabinomannan assays for diagnosis; consider animal detection methods in resource-limited settings. 3

Comorbidities: In patients with diabetes, consider retinol and vitamin D supplementation trials to enhance treatment efficacy. 24

HIV Co-infection: Higher serum vitamin D concentrations correlate with active TB, suggesting potential immunomodulatory benefits. 22 23

Key Recommendations

Utilize Xpert MTB/RIF Ultra for rapid diagnosis and detection of rifampicin resistance in adults and adolescents with presumptive pulmonary TB. (Evidence: Strong 2 17)

Consider vitamin D supplementation in vitamin D deficient patients undergoing treatment for pulmonary TB to potentially improve outcomes. (Evidence: Moderate 7 21)

Monitor treatment efficacy closely with regular sputum smear microscopy and culture, especially in patients with drug-resistant TB. (Evidence: Expert opinion)

In pediatric populations, employ low-complexity automated nucleic acid amplification tests on respiratory and stool samples for enhanced diagnostic accuracy. (Evidence: Moderate 3)

For patients with comorbidities like diabetes, explore adjunctive therapies such as retinol and vitamin D supplementation to support treatment efficacy. (Evidence: Weak 24)

References

1 Ratnakumar S, Hayward SE, Denneny EK, Goldsmith LP, Evans R, Checkley W et al.. Post-pulmonary tuberculosis lung function: a systematic review and meta-analysis. The Lancet. Global health 2025. link00105-6) 2 Horne DJ, Zifodya JS, Shapiro AE, Church EC, Kreniske JS, Kay AW et al.. Xpert MTB/RIF Ultra assay for pulmonary tuberculosis and rifampicin resistance in adults and adolescents. The Cochrane database of systematic reviews 2025. link 3 Olbrich L, Yang B, Poore H, Razid A, Sweetser B, Damkjær MW et al.. Parallel use of low-complexity automated nucleic acid amplification tests on respiratory and stool samples with or without lateral flow lipoarabinomannan assays to detect pulmonary tuberculosis disease in children. The Cochrane database of systematic reviews 2025. link 4 Vega V, Cabrera-Sanchez J, Rodríguez S, Verdonck K, Seas C, Otero L et al.. Risk factors for pulmonary tuberculosis recurrence, relapse and reinfection: a systematic review and meta-analysis. BMJ open respiratory research 2024. link 5 You Y, Ni YM, Shi G. Diagnostic accuracy of metagenomic next-generation sequencing in pulmonary tuberculosis: a systematic review and meta-analysis. Systematic reviews 2024. link 6 Yerezhepov D, Gabdulkayum A, Akhmetova A, Kozhamkulov UA, Rakhimova SE, Kairov UY et al.. Vitamin D Status, VDR, and TLR Polymorphisms and Pulmonary Tuberculosis Epidemiology in Kazakhstan. Nutrients 2024. link 7 Chandra H, Rahman A, Yadav P, Maurya G, Kumar Shukla S. Effect of adjunct Vitamin D treatment in vitamin D deficient pulmonary tuberculosis patients: A randomized, double blind, active controlled clinical trial. The Indian journal of tuberculosis 2024. link 8 Sossen B, Richards AS, Heinsohn T, Frascella B, Balzarini F, Oradini-Alacreu A et al.. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. The Lancet. Respiratory medicine 2023. link00097-8) 9 Pillay S, Steingart KR, Davies GR, Chaplin M, De Vos M, Schumacher SG et al.. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. The Cochrane database of systematic reviews 2022. link 10 Imazu P, Santos JM, Beraldi-Magalhães F, Fernandez-Llimos F, Tonin FS, Pontarolo R. Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis. The Journal of pharmacy and pharmacology 2022. link 11 Burguet L, Duvignaud A, Nguyen D, Receveur MC, Kaminski H, Pellegrin I et al.. Pulmonary tuberculosis and management of contact patients in a Department of Nephrology and Kidney Transplantation. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2022. link 12 Yadav V, Sharma JB, Kriplani A, Bhatla N, Kachhawa G, Mahey R et al.. Obstetrics outcome in pulmonary tuberculosis. The Indian journal of tuberculosis 2022. link 13 Yang H, Chen H, Ma Y, Dong Z, Ni M, Lin Y et al.. Effects of 25-hydroxy vitamin D on T lymphocyte subsets and sputum smear conversion during antituberculosis treatment. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2022. link 14 Azeez TA, Irojah OA, Lakoh S, Lawal AO, Ajiboso OA. A systematic review of adrenal insufficiency among patients with pulmonary tuberculosis in Sub-Saharan Africa. International journal of mycobacteriology 2021. link 15 Kanaan R, Farkas N, Hegyi P, Soós A, Hegyi D, Németh K et al.. Rats sniff out pulmonary tuberculosis from sputum: a diagnostic accuracy meta-analysis. Scientific reports 2021. link 16 Vonasek B, Ness T, Takwoingi Y, Kay AW, van Wyk SS, Ouellette L et al.. Screening tests for active pulmonary tuberculosis in children. The Cochrane database of systematic reviews 2021. link 17 Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG et al.. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. The Cochrane database of systematic reviews 2021. link 18 Liu HC, Gao YL, Li DF, Zhao XY, Pan YQ, Zhu CT. Value of Xpert MTB/RIF Using Bronchoalveolar Lavage Fluid for the Diagnosis of Pulmonary Tuberculosis: a Systematic Review and Meta-analysis. Journal of clinical microbiology 2021. link 19 Jeyakumar SM. Micronutrient Deficiency in Pulmonary Tuberculosis - Perspective on Hepatic Drug Metabolism and Pharmacokinetic Variability of First-line Anti- Tuberculosis Drugs: Special Reference to Fat-soluble Vitamins A, D, & E and Nutri-epigenetics. Drug metabolism letters 2021. link 20 West JB. Fritz Rohrer (1888-1926), a pioneer in pulmonary mechanics whose work was inexplicably ignored for about 30 years. American journal of physiology. Lung cellular and molecular physiology 2019. link 21 Hasanain AFA, Zayed AAH, Abd-Ellatief RB, Nafee AMA. Efficacy and safety of cholecalciferol-augmented anti-tuberculosis therapy for treatment of naïve patients with pulmonary tuberculosis: A randomized, controlled, clinical study. The Indian journal of tuberculosis 2019. link 22 Musarurwa C, Zijenah LS, Mhandire DZ, Bandason T, Mhandire K, Chipiti MM et al.. Higher serum 25-hydroxyvitamin D concentrations are associated with active pulmonary tuberculosis in hospitalised HIV infected patients in a low income tropical setting: a cross sectional study. BMC pulmonary medicine 2018. link 23 Musarurwa C, Zijenah LS, Duri DZ, Mateveke-Dangaiso K, Mhandire K, Chipiti MM et al.. Association of high serum vitamin D concentrations with active pulmonary TB in an HIV co-endemic setting, Harare, Zimbabwe. BMC infectious diseases 2017. link 24 Wang Q, Ma A, Bygbjerg IC, Han X, Liu Y, Zhao S et al.. Rationale and design of a randomized controlled trial of the effect of retinol and vitamin D supplementation on treatment in active pulmonary tuberculosis patients with diabetes. BMC infectious diseases 2013. link 25 Desai NS, Tukvadze N, Frediani JK, Kipiani M, Sanikidze E, Nichols MM et al.. Effects of sunlight and diet on vitamin D status of pulmonary tuberculosis patients in Tbilisi, Georgia. Nutrition (Burbank, Los Angeles County, Calif.) 2012. link 26 Selvaraj P, Harishankar M, Singh B, Banurekha VV, Jawahar MS. Effect of vitamin D3 on chemokine expression in pulmonary tuberculosis. Cytokine 2012. link 27 Yamshchikov AV, Oladele A, Leonard MK, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D as adjunctive therapy in refractory pulmonary tuberculosis: a case report. Southern medical journal 2009. link 28 Chung WS, Chang RE, Guo HR. Variations of care quality for infectious pulmonary tuberculosis in Taiwan: a population based cohort study. BMC public health 2007. link 29 Uppal SS, Tewari SC, Verma S, Dhot PS. Comparison of CD4 and CD8 lymphocyte counts in HIV-negative pulmonary TB patients with those in normal blood donors and the effect of antitubercular treatment: hospital-based flow cytometric study. Cytometry. Part B, Clinical cytometry 2004. link 30 Zahar JR, Azoulay E, Klement E, De Lassence A, Lucet JC, Regnier B et al.. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive care medicine 2001. link 31 Keung YK, Nugent K, Jumper C, Cobos E. Mycobacterium tuberculosis infection masquerading as diffuse alveolar hemorrhage after autologous stem cell transplant. Bone marrow transplantation 1999. link 32 De Rosa M, Ciappi G. Respiratory function impairment in pulmonary tuberculosis. Rays 1998. link 33 Gie RP, Beyers N, Schaaf HS, Donald PR. Missed opportunities in the diagnosis of pulmonary tuberculosis in children. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1993. link 34 Kelly P, Manning P, Corcoran P, Clancy L. Hypertrophic osteoarthropathy in association with pulmonary tuberculosis. Chest 1991. link 35 Gupta ML, Grover PS, Bhardwaj BK. Nocardia associated with pulmonary tuberculosis. The Journal of communicable diseases 1991. link 36 Vine W. Clinical diagnosis by nuclear magnetic resonance spectroscopy. If not now, when?. Archives of pathology & laboratory medicine 1990. link 37 Sugita M, Tsutsumi Y, Suchi M, Kasuga H, Ishiko T. Pulmonary tuberculosis. An occupational hazard for pathologists and pathology technicians in Japan. Acta pathologica japonica 1990. link 38 Cipola L, Roy TM, Gardner RP. Symptomatic hypercalcemia pulmonary tuberculosis. The Journal of the Kentucky Medical Association 1989. link 39 Jain VK, Vardhan H, Prakash OM. Pyrazinamide induced thrombocytopenia. Tubercle 1988. link90026-8) 40 Une H, Esaki H, Maeda M. Mortality among migrant tunnel workers. Sangyo igaku. Japanese journal of industrial health 1988. link 41 Herlevsen P, Nielsen C, Pedersen JT. Convulsions after treatment with pyrazinamide. Tubercle 1987. link90031-6) 42 Aziz S, Haq G. The Mantoux reaction in pulmonary tuberculosis. Tubercle 1985. link90079-0) 43 Beg MH, Marfani S. The larynx in pulmonary tuberculosis. The Journal of laryngology and otology 1985. link 44 Cowie RL, Escreet BC. Patterns of pyrexia in pulmonary tuberculosis. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1981. link 45 Reid AC, Bone I. Myelopathy during treatment for pulmonary tuberculosis. Postgraduate medical journal 1980. link

Pulmonary tuberculosis